CY2010017I2 - Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης - Google Patents

Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης

Info

Publication number
CY2010017I2
CY2010017I2 CY2010017C CY2010017C CY2010017I2 CY 2010017 I2 CY2010017 I2 CY 2010017I2 CY 2010017 C CY2010017 C CY 2010017C CY 2010017 C CY2010017 C CY 2010017C CY 2010017 I2 CY2010017 I2 CY 2010017I2
Authority
CY
Cyprus
Prior art keywords
preparing
new protein
protein
new
Prior art date
Application number
CY2010017C
Other languages
Greek (el)
English (en)
Other versions
CY2010017I1 (el
Original Assignee
Daiichi Sankyo Compamy Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27525882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2010017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Compamy Limited filed Critical Daiichi Sankyo Compamy Limited
Publication of CY2010017I1 publication Critical patent/CY2010017I1/el
Publication of CY2010017I2 publication Critical patent/CY2010017I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
CY2010017C 1997-04-15 2010-11-30 Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης CY2010017I2 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP15143497 1997-06-09
JP21789797 1997-08-12
JP22480397 1997-08-21
JP33224197 1997-12-02
PCT/JP1998/001728 WO1998046644A1 (fr) 1997-04-15 1998-04-15 Nouvelle proteine et methode de production associee

Publications (2)

Publication Number Publication Date
CY2010017I1 CY2010017I1 (el) 2011-02-02
CY2010017I2 true CY2010017I2 (el) 2012-01-25

Family

ID=27525882

Family Applications (1)

Application Number Title Priority Date Filing Date
CY2010017C CY2010017I2 (el) 1997-04-15 2010-11-30 Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης

Country Status (21)

Country Link
US (7) US7527790B2 (enExample)
EP (3) EP1657255B1 (enExample)
JP (7) JP3523650B2 (enExample)
KR (1) KR100496063B1 (enExample)
CN (1) CN1138786C (enExample)
AT (1) ATE328006T1 (enExample)
AU (1) AU735355B2 (enExample)
CA (2) CA2781623A1 (enExample)
CY (1) CY2010017I2 (enExample)
DE (2) DE122010000049I1 (enExample)
DK (1) DK0911342T4 (enExample)
ES (1) ES2263204T5 (enExample)
FR (1) FR10C0048I2 (enExample)
HU (3) HU229841B1 (enExample)
IL (1) IL127115A (enExample)
LU (1) LU91759I2 (enExample)
NO (2) NO322632B1 (enExample)
NZ (1) NZ332995A (enExample)
PT (1) PT911342E (enExample)
RU (1) RU2238949C2 (enExample)
WO (1) WO1998046644A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
ATE399861T1 (de) * 1996-12-13 2008-07-15 Schering Corp Oberflächenantigene aus säugern
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2781623A1 (en) 1997-04-15 1998-10-22 Daiichi Sankyo Company, Limited Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
ID23855A (id) * 1997-04-16 2000-05-25 Amgen Inc Protein pengikat osteoprotegerin dan reseptor
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ES2317694T3 (es) * 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
EP1127578A4 (en) 1998-10-28 2004-12-15 Sankyo Co MEDICINE FOR BONE METABOLIC DEVIATIONS
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
MXPA02008144A (es) † 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
EP1377610A2 (en) 2001-04-03 2004-01-07 Société des Produits Nestlé S.A. Osteoprotegerin in milk
NO345566B1 (no) 2001-06-26 2021-04-19 Amgen Inc OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
MXPA05006147A (es) * 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
BRPI0506726B8 (pt) 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2324425C2 (ru) * 2005-08-30 2008-05-20 Государственное образовательное учреждение "Институт усовершенствования врачей" Министерства здравоохранения и социального развития Способ профилактики рождения больных остеопетрозом детей
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN101384733A (zh) * 2006-02-13 2009-03-11 奥尔加·奥尔纳茨基 通过元素分析实施的基因表达检测
EP2020445B1 (en) 2006-05-12 2013-01-02 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
AU2007305855A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble RANKL with epitope tag
EP2165716B1 (en) 2007-06-05 2014-11-12 Oriental Yeast Co., Ltd. Novel bone mass increasing agent
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
EP2320945A4 (en) * 2008-07-30 2013-02-27 Emergent Biosolutions Inc STABLE MILZBRANDIMPFSTOFFFORMULIERUNGEN
EP2343087B1 (en) 2008-09-30 2018-07-18 Oriental Yeast Co., Ltd. Novel inducer of chondrocyte proliferation and differentiation
US20120018338A1 (en) * 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
US8575316B2 (en) 2009-04-09 2013-11-05 Daiichi Sankyo Company, Limited Anti-Siglec-15 antibody
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
BR112013008255A2 (pt) 2010-10-05 2018-09-25 Daiichi Sankyo Co Ltd anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
WO2012133914A1 (ja) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤
EP2827879B1 (en) 2012-03-21 2019-05-08 Dana-Farber Cancer Institute, Inc. Isolation and use of human lymphoid organ-derived suppressive stromal cells
HK1204657A1 (en) 2012-03-30 2015-11-27 Daiichi Sankyo Company, Limited Anti-siglec15 antibody with modified cdr
EP2875051B1 (en) 2012-07-19 2019-02-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies
US10246513B2 (en) 2013-08-07 2019-04-02 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
RU2747929C2 (ru) * 2016-09-13 2021-05-17 ИэндЭС ХЕЛТКЕАР КО., ЛТД. Моноклональное антитело, специфически связывающееся с тиоредоксином-1, и его применение
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN111205354B (zh) * 2020-01-22 2021-01-22 天津科技大学 一种提高异源蛋白分泌量的信号肽突变体及其构建方法与用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
WO1986000922A1 (en) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3356775B2 (ja) 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
ATE202571T1 (de) 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
EP0727211A1 (en) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
ATE399861T1 (de) * 1996-12-13 2008-07-15 Schering Corp Oberflächenantigene aus säugern
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2781623A1 (en) 1997-04-15 1998-10-22 Daiichi Sankyo Company, Limited Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ID23855A (id) 1997-04-16 2000-05-25 Amgen Inc Protein pengikat osteoprotegerin dan reseptor
EP0980432A1 (en) 1997-05-01 2000-02-23 Amgen, Inc. Chimeric opg polypeptides
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ES2317694T3 (es) 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
JP2003508491A (ja) 1999-09-03 2003-03-04 アムジエン・インコーポレーテツド 癌および癌に関連する骨損失の予防または治療のための組成物および方法
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
NO345566B1 (no) 2001-06-26 2021-04-19 Amgen Inc OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Also Published As

Publication number Publication date
US20070009520A1 (en) 2007-01-11
DE69834699T2 (de) 2007-05-16
ATE328006T1 (de) 2006-06-15
KR20040004509A (ko) 2004-01-13
US20030208045A1 (en) 2003-11-06
US20050208580A1 (en) 2005-09-22
ES2263204T3 (es) 2006-12-01
HU0800628D0 (en) 2010-06-28
KR100496063B1 (ko) 2005-06-21
NO2010021I1 (no) 2011-01-10
JP2012041345A (ja) 2012-03-01
JP2009029834A (ja) 2009-02-12
EP0911342B2 (en) 2013-05-22
CY2010017I1 (el) 2011-02-02
IL127115A (en) 2013-08-29
CA2781623A1 (en) 1998-10-22
JP2005176847A (ja) 2005-07-07
US20120329671A1 (en) 2012-12-27
ES2263204T5 (es) 2013-10-14
NO985848D0 (no) 1998-12-14
HU229476B1 (en) 2014-01-28
JP5593407B2 (ja) 2014-09-24
JP4878616B2 (ja) 2012-02-15
AU735355C (en) 1998-11-11
EP1657255A1 (en) 2006-05-17
US20080187540A9 (en) 2008-08-07
DE122010000049I1 (de) 2011-05-05
US20100136011A1 (en) 2010-06-03
AU735355B2 (en) 2001-07-05
JP2009013177A (ja) 2009-01-22
NO985848L (no) 1999-02-15
US7192718B2 (en) 2007-03-20
FR10C0048I1 (enExample) 2011-01-14
JP2004041195A (ja) 2004-02-12
CN1222917A (zh) 1999-07-14
EP0911342A4 (en) 2002-11-27
JP3523650B2 (ja) 2004-04-26
IL127115A0 (en) 1999-09-22
RU2238949C2 (ru) 2004-10-27
PT911342E (pt) 2006-08-31
EP0911342A1 (en) 1999-04-28
EP2336168A1 (en) 2011-06-22
JP2013139465A (ja) 2013-07-18
LU91759I9 (enExample) 2019-01-02
JP3935861B2 (ja) 2007-06-27
JP4230993B2 (ja) 2009-02-25
EP0911342B1 (en) 2006-05-31
HUP0000717A2 (hu) 2000-06-28
NO322632B1 (no) 2006-11-06
JP5285751B2 (ja) 2013-09-11
CA2257247C (en) 2012-09-11
US7527790B2 (en) 2009-05-05
HUS1400027I1 (hu) 2016-10-28
FR10C0048I2 (fr) 2013-08-16
DK0911342T4 (da) 2013-07-29
DE69834699T3 (de) 2013-11-14
US20050003457A1 (en) 2005-01-06
AU6851898A (en) 1998-11-11
US20030176647A1 (en) 2003-09-18
EP1657255B1 (en) 2014-07-30
WO1998046644A1 (fr) 1998-10-22
JP4355357B2 (ja) 2009-10-28
US7449185B2 (en) 2008-11-11
NZ332995A (en) 2000-07-28
DK0911342T3 (da) 2006-08-21
CN1138786C (zh) 2004-02-18
DE69834699D1 (de) 2006-07-06
LU91759I2 (fr) 2011-01-24
HU229841B1 (en) 2014-09-29
NO2010021I2 (no) 2015-03-09
CA2257247A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
CY2010017I2 (el) Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
DE69834401D1 (de) Businterfacesystem und verfahren
DE59810847D1 (de) Verfahren zur form- und volumengebung von humanhaaren
FI973402L (fi) Uusia proteiineja ja menetelmiä proteiinien tuottamiseksi
DE69835020D1 (de) Plasmabrenner und verwendungsverfahren dieses plasmabrenners
ATE253116T1 (de) Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern
EE9900357A (et) Geenisekvenaator ja meetodid
DE69840199D1 (de) Chirurgisches instrument und verfahren
DE69838230D1 (de) Frequenzumsetzer und verfahren
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
ATE351910T1 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
DE69707325D1 (de) Bilderzeugungsmaterial und Verfahren
FI962932L (fi) Ankkuriproteiinifunktion modulaattoreita
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
DE69830556D1 (de) Verfahren zur Bestimmung von glykosylierten Proteinen
DE69838667D1 (de) Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel
NO971505D0 (no) Trofinin og trofininhjelperproteiner
CY2005003I2 (el) Mεθοδοι και ενδιαμεσα χρησιμα για κατασκευη αντιφολικων
ID18300A (id) Metoda penemperan
DE69524527D1 (de) AIDS-hemmende Arzneizubereitung und Verfahren
DE19749117B4 (de) Pleuelstange und Herstellungsverfahren dafür
NO960766D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
FI980945L (fi) Menetelmä proteiinien eristämiseksi ja muuntelemiseksi
DE69718579D1 (de) Bestimmung von Proteinen